1. Home
  2. ALTI vs AKBA Comparison

ALTI vs AKBA Comparison

Compare ALTI & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALTI
  • AKBA
  • Stock Information
  • Founded
  • ALTI 2020
  • AKBA 2007
  • Country
  • ALTI United States
  • AKBA United States
  • Employees
  • ALTI N/A
  • AKBA N/A
  • Industry
  • ALTI Investment Managers
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALTI Finance
  • AKBA Health Care
  • Exchange
  • ALTI Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • ALTI 302.7M
  • AKBA 336.2M
  • IPO Year
  • ALTI N/A
  • AKBA 2014
  • Fundamental
  • Price
  • ALTI $3.26
  • AKBA $2.06
  • Analyst Decision
  • ALTI
  • AKBA Strong Buy
  • Analyst Count
  • ALTI 0
  • AKBA 3
  • Target Price
  • ALTI N/A
  • AKBA $6.50
  • AVG Volume (30 Days)
  • ALTI 128.4K
  • AKBA 5.0M
  • Earning Date
  • ALTI 05-09-2025
  • AKBA 05-08-2025
  • Dividend Yield
  • ALTI N/A
  • AKBA N/A
  • EPS Growth
  • ALTI N/A
  • AKBA N/A
  • EPS
  • ALTI N/A
  • AKBA N/A
  • Revenue
  • ALTI $206,935,000.00
  • AKBA $160,180,000.00
  • Revenue This Year
  • ALTI $25.79
  • AKBA $22.50
  • Revenue Next Year
  • ALTI $9.88
  • AKBA $43.23
  • P/E Ratio
  • ALTI N/A
  • AKBA N/A
  • Revenue Growth
  • ALTI N/A
  • AKBA N/A
  • 52 Week Low
  • ALTI $2.33
  • AKBA $0.80
  • 52 Week High
  • ALTI $5.45
  • AKBA $2.89
  • Technical
  • Relative Strength Index (RSI)
  • ALTI 55.89
  • AKBA 56.65
  • Support Level
  • ALTI $2.75
  • AKBA $1.52
  • Resistance Level
  • ALTI $3.40
  • AKBA $1.86
  • Average True Range (ATR)
  • ALTI 0.28
  • AKBA 0.15
  • MACD
  • ALTI 0.06
  • AKBA 0.02
  • Stochastic Oscillator
  • ALTI 82.05
  • AKBA 88.52

About ALTI AlTi Global Inc.

AlTi Global Inc is an independent wealth and asset manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services. The firm has business which is organized into two business segments namely: Wealth & Capital Solutions and International Real Estate segment includes providing holistic solutions for wealth management clients through comprehensive range of wealth management services, including investment management and advisory services. International Real Estate segment includes assist investors with real estate co-investments, structuring and selecting partners with a proven track record with risk adjusted return characteristics.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: